Suppr超能文献

树突状细胞上的PD-1表达会抑制CD8 T细胞功能和抗肿瘤免疫。

PD-1 expression on dendritic cells suppresses CD8 T cell function and antitumor immunity.

作者信息

Lim Tong Seng, Chew Valerie, Sieow Je Lin, Goh Siting, Yeong Joe Poh-Sheng, Soon Ai Ling, Ricciardi-Castagnoli Paola

机构信息

Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (ASTAR), 8A Biomedical Grove, IMMUNOS Building #4, BIOPOLIS, Singapore; A. Menarini Biomarkers Singapore Pte Ltd, 30 Pasir Panjang Road, #08-32, Mapletree Business City, Singapore.

SingHealth Translational Immunology and Inflammation Center (STIIC), Duke-NUS Medical School, The Academia , 20 College Road, Discovery Tower Level 8 , Singapore.

出版信息

Oncoimmunology. 2015 Aug 31;5(3):e1085146. doi: 10.1080/2162402X.2015.1085146. eCollection 2016 Mar.

Abstract

Programmed death one (PD-1) is a well-established co-inhibitory regulator that suppresses proliferation and cytokine production of T cells. Despite remarkable progress in delineating the functional roles of PD-1 on T lymphocytes, little is known about the regulatory role of PD-1 expressed on myeloid cells such as dendritic cells (DCs). Here, we show that CD8 T cells can be more potently activated to secrete IL-2 and IFNγ by PD-1-deficient DCs compared to wild-type DCs. Adoptive transfer of PD-1-deficient DCs demonstrated their superior capabilities in inducing antigen-specific CD8 T cell proliferation . In addition, we provide first evidence demonstrating the existence of peripheral blood DCs and CD11c tumor-infiltrating myeloid cells that co-express PD-1 in patients with hepatocellular carcinoma (HCC). The existence of PD-1-expressing HCC-infiltrating DCs (HIDCs) was further supported in a mouse model of HCC. Intratumoral transfer of PD-1-deficient DCs rendered recipient mice resistant to the growth of HCC by promoting tumor-infiltrating CD8 effector T cells to secrete perforin and granzyme B. This novel finding provides a deeper understanding of the role of PD-1 in immune regulation and has significant implications for cancer immunotherapies targeting PD-1.

摘要

程序性死亡蛋白1(PD-1)是一种成熟的共抑制调节因子,可抑制T细胞的增殖和细胞因子产生。尽管在阐明PD-1对T淋巴细胞的功能作用方面取得了显著进展,但对于树突状细胞(DC)等髓系细胞上表达的PD-1的调节作用知之甚少。在此,我们表明,与野生型DC相比,PD-1缺陷型DC能更有效地激活CD8 T细胞分泌白细胞介素-2(IL-2)和γ干扰素(IFNγ)。过继转移PD-1缺陷型DC证明了它们在诱导抗原特异性CD8 T细胞增殖方面具有更强的能力。此外,我们首次提供证据证明,在肝细胞癌(HCC)患者中存在共表达PD-1的外周血DC和CD11c肿瘤浸润髓系细胞。在HCC小鼠模型中进一步证实了表达PD-1的HCC浸润性DC(HIDC)的存在。瘤内转移PD-1缺陷型DC通过促进肿瘤浸润的CD8效应T细胞分泌穿孔素和颗粒酶B,使受体小鼠对HCC生长产生抗性。这一新发现为深入了解PD-1在免疫调节中的作用提供了依据,对针对PD-1的癌症免疫疗法具有重要意义。

相似文献

1
PD-1 expression on dendritic cells suppresses CD8 T cell function and antitumor immunity.
Oncoimmunology. 2015 Aug 31;5(3):e1085146. doi: 10.1080/2162402X.2015.1085146. eCollection 2016 Mar.
4
/ Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti-PD-1 Efficacy.
Cancer Immunol Res. 2020 Jan;8(1):81-93. doi: 10.1158/2326-6066.CIR-19-0210. Epub 2019 Oct 30.
5
Dendritic Cells Exposed to Triiodothyronine Deliver Pro-Inflammatory Signals and Amplify IL-17-Driven Immune Responses.
Cell Physiol Biochem. 2019;52(2):354-367. doi: 10.33594/000000025. Epub 2019 Feb 28.
6
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Front Immunol. 2018 Jan 22;9:14. doi: 10.3389/fimmu.2018.00014. eCollection 2018.
7
Negative role of inducible PD-1 on survival of activated dendritic cells.
J Leukoc Biol. 2014 Apr;95(4):621-9. doi: 10.1189/jlb.0813443. Epub 2013 Dec 6.
9
CD8 cytotoxic T lymphocytes in cancer immunotherapy: A review.
J Cell Physiol. 2019 Jun;234(6):8509-8521. doi: 10.1002/jcp.27782. Epub 2018 Nov 22.

引用本文的文献

2
Myeloid cells in chronic liver inflammation.
Cell Mol Immunol. 2025 Jul 28. doi: 10.1038/s41423-025-01324-4.
3
Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors.
Ther Adv Med Oncol. 2025 Jun 19;17:17588359251347469. doi: 10.1177/17588359251347469. eCollection 2025.
4
Dendritic cell-based immunotherapy for head and neck squamous cell carcinoma: advances and challenges.
Front Immunol. 2025 May 26;16:1573635. doi: 10.3389/fimmu.2025.1573635. eCollection 2025.
7
Engineered Immunologic Niche Monitors Checkpoint Blockade Response and Probes Mechanisms of Resistance.
Immunomedicine. 2024 Jun;4(1). doi: 10.1002/imed.1052. Epub 2024 Jun 6.
9
"Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity.
Cancer Commun (Lond). 2024 Jul;44(7):791-832. doi: 10.1002/cac2.12579. Epub 2024 Jun 23.
10
Insufficient PD-1 expression during active autoimmune responses: a deep single-cell proteomics analysis in inflammatory arthritis.
Front Immunol. 2024 Jun 7;15:1403680. doi: 10.3389/fimmu.2024.1403680. eCollection 2024.

本文引用的文献

1
Clinical blockade of PD1 and LAG3--potential mechanisms of action.
Nat Rev Immunol. 2015 Jan;15(1):45-56. doi: 10.1038/nri3790.
2
Regulation of immune reactivity by intercellular transfer.
Front Immunol. 2014 Mar 28;5:112. doi: 10.3389/fimmu.2014.00112. eCollection 2014.
3
Negative role of inducible PD-1 on survival of activated dendritic cells.
J Leukoc Biol. 2014 Apr;95(4):621-9. doi: 10.1189/jlb.0813443. Epub 2013 Dec 6.
5
Advances in targeting cell surface signalling molecules for immune modulation.
Nat Rev Drug Discov. 2013 Feb;12(2):130-46. doi: 10.1038/nrd3877.
6
Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients.
J Natl Cancer Inst. 2012 Dec 5;104(23):1796-807. doi: 10.1093/jnci/djs436. Epub 2012 Nov 29.
7
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
8
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
9
Tumor immunotherapy directed at PD-1.
N Engl J Med. 2012 Jun 28;366(26):2517-9. doi: 10.1056/NEJMe1205943. Epub 2012 Jun 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验